Tramway Venture Partners
Venture capitalNew Mexico · Seed–Series A · 8 people tracked
Investment thesis
The firm invests in life sciences, using the technology-rich Southwestern United States, and particularly New Mexico, as its base for building disruptive life science companies. It emphasizes finding opportunities in out-of-the-way places where competition may be lower and untapped potential exists.
Source: firm website, verified Aug 3, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 9 of 15 portfolio companiesBiotech ×6Energy ×3Medical Devices ×2AI & Machine Learning ×1Digital Health ×1Hardware ×1Healthtech ×1
HQs:United States×11
Investments · 15 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 32024 · 12023 · 12020 · 12018 · 12015 · 19 dated
BiotechAlbuquerque, US
Joseph Patti(Executive Officer, Director)Ebetuel Pallares(Executive Officer, Director)Brian Birk(Executive Officer, Director)Faith Charles(Director)Debora E Ramirez(Executive Officer)
Board seatWaneta Tuttle· per SEC Form D · $7.5M raise · filed Aug 2019
BiotechAlbuquerque, US
Stephen Brueck(Executive Officer, Promoter)Emily Milsovic(Executive Officer, Director)Steven R.J. Brueck(Director)Scott L. Goldman(Executive Officer, Director, Promoter)Zachary Lerner(Executive Officer)
BoardDavid Blivin(Director)
Board seatWaneta TuttleWaneta Tuttle· per SEC Form D · $5.7M raise · filed Dec 2025
EnergyArvada, US
Brent Lewis(Executive Officer, Director)Scott Frazier(Executive Officer, Director)Alex Lau(Director)
Board seatJohn Rockwell· per SEC Form D · $4M raise · filed Mar 2020
Circular Genomics develops a proprietary platform using circular RNA biomarkers to enable early detection and understanding of neurological diseases through blood tests.
AI & Machine LearningBiotechDigital HealthMedical DevicesAlbuquerque, US
Alexander Hafez(Executive Officer, Director, Promoter)Nikolaos Mellios(Director, Promoter)
Board seatWaneta Tuttle· per SEC Form D · $15M raise · filed Jan 2024
EnergyDover, US
Brent Lewis(Executive Officer, Director)Miles Abarr(Executive Officer, Director)
BoardJason Williams(Director)Alex Lau(Director)
Board seatJohn Rockwell· per SEC Form D · $2.3M raise · filed Sep 2025
EnergySanta Clara, US
Angiolo Laviziano(Director)Andre Willis(Executive Officer, Director)Chuck Abronson(Director)John Hall(Director)Lutz Henckels(Executive Officer, Director)
Board seatJohn Rockwell· per SEC Form D · $11.1M raise · filed Sep 2015
Houghton, US
Lyon B. King(Executive Officer, Director)Jorge Ramos(Director)Jason Sommerville(Director)
BoardKanwal Rekhi(Director)Adam Sharkawy(Director)
Board seatJohn Rockwell· per SEC Form D · $37.1M raise · filed Dec 2025
BiotechSanta Fe, US
Davin Isakson(Executive Officer)Alan Nolley(Executive Officer, Director, Promoter)Jeremy Stueven(Executive Officer, Director, Promoter)Nathan Wyatt(Executive Officer)Jeffrey Wigdahl(Executive Officer)Sydnie Keddington(Director)
Board seatWaneta Tuttle· per SEC Form D · $3M raise · filed Feb 2026
Wavefront Dynamics makes the WaveDȳn Vision Analyzer, an optical measurement instrument that captures ten eye measurements in five seconds to detect higher-order aberrations and irregularities.
BiotechHardwareHealthtechMedical DevicesAlbuquerque, US
R. Terry Dunlay(Director)Daniel R. Neal(Executive Officer, Director, Promoter)
Board seatWaneta Tuttle· per SEC Form D · $7.2M raise · filed Sep 2023
BiotechAlbuquerque, US
Travis Woods(Executive Officer)Steven Graves(Executive Officer, Director, Promoter)R. Terry Dunlay(Director)James Freyer(Executive Officer)David Blivin(Director)
BoardWaneta Tuttle(Director)
Automated, data-driven biohazard disinfection platform field-tested across multiple industries.
Developing advanced nanochip systems for direct reading of DNA and study of single-cell epigenetics.
Develops proprietary synthetic population models and simulation engines for predictive forecasting and decision-making.
Albuquerque, US
Noel Greenberger(Executive Officer, Director)Yun Li(Executive Officer, Director)
BoardChris Japp(Director)Paul Atkins(Director)Robert Calvin Goforth(Director)
Developing instruments for ophthalmology to measure and improve visual performance.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companiesCircular Genomics · finsmes.com · Dec 1, 2025
Frequently asked questions
- What stage does Tramway Venture Partners invest at?
- Tramway Venture Partners invests at the Seed, Series A stages.
- What is Tramway Venture Partners's typical check size?
- Tramway Venture Partners typically writes checks of $30M.
- What sectors does Tramway Venture Partners focus on?
- Tramway Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Tramway Venture Partners located?
- Tramway Venture Partners is headquartered in New Mexico, US.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Future Positive Capital's portfolio page showcasing companies across health, climate, and deeptech sectors.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.